KDC-MN-371 – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

Liposomal glutathione is the body’s master antioxidant (a small protein called glutathione, or GSH) packaged inside tiny fat bubbles called liposomes. The trick is delivery. Plain oral glutathione is largely destroyed in the gut, so the liposome shell is meant to protect it long enough to reach the bloodstream and possibly take a lymphatic shortcut. A handful of small clinical studies suggest it raises blood and intracellular glutathione better than plain oral glutathione, but the picture is far from settled. Many researchers argue NAC (which lets cells build their own glutathione) does the same job for less money. Used in oxidative-stress research and as a supplement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

31/100

Delivery-optimized GSH formulation with modest clinical signal but no new biology

Look, glutathione is about as foundational as it gets in redox biology. The GSH/GSSG ratio, phase II detoxification, glutathione peroxidase cascades – this is textbook biochemistry from the 1970s and 1980s. Liposomal encapsulation is a genuinely clever fix for a real problem: native oral glutathione gets chewed up by intestinal proteases before it reaches systemic circulation, so plasma elevation from unprotected oral dosing has historically been poor.

The phosphatidylcholine encapsulation story makes mechanistic sense. Protecting the tripeptide from proteolytic degradation, potentially routing absorption through the chylomicron and lymphatic pathway – its a plausible engineering solution to a known limitation. And published trials do show liposomal formulations outperforming plain oral GSH on plasma and intracellular markers. Richie et al. (2015) in the European Journal of Nutrition is probably the most-cited work here, showing dose-dependent GSH increases over four weeks in healthy adults. Thats real data, not marketing copy.

Here’s the thing though: “better than plain oral glutathione” is a low bar, and it doesn’t resolve whether this is the right tool. NAC raises glutathione via de novo synthesis rather than direct delivery, carries several decades of clinical evidence including robust data in acetaminophen overdose and pulmonary conditions, and costs a fraction of liposomal GSH. The head-to-head is genuinely unsettled in the literature. That debate is real, but it’s a debate about delivery logistics, not new biology.

What we don’t see with liposomal glutathione is a novel research question it uniquely enables. For in vitro work, you add GSH directly to media. For animal depletion models, buthionine sulfoximine is the clean probe. For IV administration in human studies, established IV protocols exist. The liposomal oral form fills a specific niche – convenient, non-invasive, better absorbed than plain oral – but that’s a product story, not a research frontier.

The novelty here is in delivery engineering, and even that isn’t particularly fresh. Liposomal formulations have been a pharmaceutical tool since the late 1960s. Applying them to glutathione is a sensible extension but doesn’t define a new area of investigation. We’re not generating new mechanistic knowledge about redox networks or glutathione metabolism with this formulation. Honestly, if your research program genuinely requires elevated systemic glutathione in a non-IV setting, this is worth knowing about. But as a compound that might anchor a research program? The science here is settled, not frontier.

Novelty: 30
Mechanism promise: 22
In-category differentiation: 38
Evidence quality: 33
Translational signal: 33
Research bench value: 35

Rationale Liposomal encapsulation addresses a real bioavailability limitation of oral glutathione, and small clinical trials confirm improved plasma levels, but the underlying mechanism is entirely settled, NAC competes on most dimensions with far deeper evidence, and the compound opens no novel research questions.

Glutathione (liposomal formulation)

L-glutathione encapsulated in phospholipid liposomes for improved oral absorption.

Abstract

Liposomal glutathione (L-glutathione encapsulated in phosphatidylcholine-based liposomes; native GSH CAS 70-18-8; molecular formula C10H17N3O6S; molecular weight 307.32) is a delivery system for the master antioxidant glutathione developed to address the poor oral bioavailability of native glutathione. The phospholipid bilayer protects the tripeptide from gastric and intestinal proteolysis and may facilitate intestinal uptake through chylomicron-mediated lymphatic absorption. Limited published clinical trials suggest improved plasma and intracellular glutathione elevation compared to non-liposomal oral forms, though comparative effectiveness against NAC (which raises GSH via biosynthesis rather than direct delivery) is debated. Used as a research-grade and supplement-grade glutathione formulation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-371Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-371

Liposomal Glutathione

Abstract

Read the full monograph